SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-221705"
 

Search: onr:"swepub:oai:DiVA.org:uu-221705" > Left Ventricular Sy...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients With Atrial Fibrillation Insights From the ARISTOTLE Trial

McMurray, John J. V. (author)
Ezekowitz, Justin A. (author)
Lewis, Basil S. (author)
show more...
Gersh, Bernard J. (author)
van Diepen, Sean (author)
Amerena, John (author)
Bartunek, Jozef (author)
Commerford, Patrick (author)
Oh, Byung-Hee (author)
Harjola, Veli-Pekka (author)
Al-Khatib, Sana M. (author)
Hanna, Michael (author)
Alexander, John H. (author)
Lopes, Renato D. (author)
Wojdyla, Daniel M. (author)
Wallentin, Lars (author)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi
Granger, Christopher B. (author)
show less...
 (creator_code:org_t)
2013
2013
English.
In: Circulation Heart Failure. - 1941-3289 .- 1941-3297. ; 6:3, s. 451-460
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background-We examined the risk of stroke or systemic embolism (SSE) conferred by heart failure (HF) and left ventricular systolic dysfunction (LVSD) in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation Trial (ARISTOTLE), as well as the effect of apixaban versus warfarin. Methods and Results-The risk of a number of outcomes, including the composite of SSE or death (to take account of competing risks) and composite of SSE, major bleeding, or death (net clinical benefit) were calculated in 3 patient groups: (1) no HF/no LVSD (n=8728), (2) HF/no LVSD (n=3207), and (3) LVSD with/without symptomatic HF (n=2736). The rate of both outcomes was highest in patients with LVSD (SSE or death 8.06; SSE, major bleeding, or death 10.46 per 100 patient-years), intermediate for HF but preserved LV systolic function (5.32; 7.24), and lowest in patients without HF or LVSD (1.54; 5.27); each comparison P<0.0001. Each outcome was less frequent in patients treated with apixaban: in all ARISTOTLE patients, the apixaban/warfarin hazard ratio for SSE or death was 0.89 (95% confidence interval, 0.81-0.98; P=0.02); for SSE, major bleed, or death it was 0.85 (0.78-0.92; P<0.001). There was no heterogeneity of treatment effect across the 3 groups. Conclusions-Patients with LVSD (with/without HF) had a higher risk of SSE or death (but similar rate of SSE) compared with patients with HF but preserved LV systolic function; both had a greater risk than patients without either HF or LVSD. Apixaban reduced the risk of both outcomes more than warfarin in all 3 patient groups.

Keyword

atrial fibrillation
heart failure
left ventricular systolic dysfunction
stroke

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view